<DOC>
	<DOCNO>NCT01513863</DOCNO>
	<brief_summary>The objective study demonstrate metronidazole 1 % topical gel effective treatment patient moderate severe rosacea .</brief_summary>
	<brief_title>A Therapeutic Equivalence Study Two Metronidazole 1 % Topical Gel Treatments Patients With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>1 . Male nonpregnant , nonlactating female , 18 year age old . 2 . Signed informed consent form , meet criteria current FDA regulation . 3 . If female child bear potential , prepare abstain sexual intercourse use reliable method contraception study ( e.g. , condom , IUD , oral , transdermal , injected implant hormonal contraceptive ) . 4 . Have moderate severe facial rosacea . 5 . Have Baseline Investigator Global Evaluation Score 3 4 . 1 . Mild facial rosacea ( le 8 inflammatory lesion face ) severe rosacea ( 50 inflammatory lesion ) 2 . Patients excessive facial hair ( beard , sideburn , moustache , etc . ) would interfere diagnosis assessment rosacea . 3 . History hypersensitivity allergy Metronidazole , ingredients formulation . 4 . Use oral retinoids ( e.g . Accutane Â® ) therapeutic vitamin A supplement great 10,000 units/day ( multivitamin allow ) within 6 month prior baseline visit . 5 . Use follow within 1 month prior baseline visit : Topical Retinoids face Systemic antibiotic know impact severity facial Rosacea Systemic Steroids 6 . The use anticoagulant therapy within 14 day prior baseline . 7 . The use antipruritic , include antihistamine within 24 hour study visit . 8 . History blood dyscrasia . 9 . Ocular rosacea ( e.g. , conjunctivitis , blepharitis , keratitis ) sufficient severity require topical systemic antibiotic . 10 . Any dermatological condition rosacea Investigator 's opinion may interfere evaluation Patient 's rosacea ( e.g. , acne , psoriasis , dermatitis ) . 11 . Females pregnant , lactate likely become pregnant study . 12 . Significant history current evidence chronic infectious disease , system disorder , organ disorder medical condition Investigator 's opinion would place study Patient undue risk participation . 13 . Any Patient ( male female ) start , change hormonal therapy within 3 month Baseline visit ( include hormonal contraceptive ) . 14 . Use high strength ( 20 % ) alphahydroxy acid facial peel type chemical facial skin peel significant cosmetic procedure within 2 month study start . 15 . Receipt drug part research study within 30 day prior dose . 16 . Employees research center Investigator . 17 . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>